Evidence map›Paper›PMID 25170205›Full record

ReviewWorld journal of gastroenterology2014

Selection criteria in resectable pancreatic cancer: a biological and morphological approach.

Domenico Tamburrino, Stefano Partelli, Stefano Crippa, Alberto Manzoni, Angela Maurizi, Massimo Falconi

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.Annals of oncology : official journal of the European Society for Medical Oncology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Domenico TamburrinoDomenico Tamburrino, Stefano Partelli, Stefano Crippa, Alberto Manzoni, Angela Maurizi, Massimo Falconi, Pancreatic Surgery Unit, Department of Surgery, Polytechnic University of Marche Region, 60126 Ancona-Torrette, Italy.
Stefano PartelliDomenico Tamburrino, Stefano Partelli, Stefano Crippa, Alberto Manzoni, Angela Maurizi, Massimo Falconi, Pancreatic Surgery Unit, Department of Surgery, Polytechnic University of Marche Region, 60126 Ancona-Torrette, Italy.
Stefano CrippaDomenico Tamburrino, Stefano Partelli, Stefano Crippa, Alberto Manzoni, Angela Maurizi, Massimo Falconi, Pancreatic Surgery Unit, Department of Surgery, Polytechnic University of Marche Region, 60126 Ancona-Torrette, Italy.
Alberto ManzoniDomenico Tamburrino, Stefano Partelli, Stefano Crippa, Alberto Manzoni, Angela Maurizi, Massimo Falconi, Pancreatic Surgery Unit, Department of Surgery, Polytechnic University of Marche Region, 60126 Ancona-Torrette, Italy.
Angela MauriziDomenico Tamburrino, Stefano Partelli, Stefano Crippa, Alberto Manzoni, Angela Maurizi, Massimo Falconi, Pancreatic Surgery Unit, Department of Surgery, Polytechnic University of Marche Region, 60126 Ancona-Torrette, Italy.
Massimo FalconiDomenico Tamburrino, Stefano Partelli, Stefano Crippa, Alberto Manzoni, Angela Maurizi, Massimo Falconi, Pancreatic Surgery Unit, Department of Surgery, Polytechnic University of Marche Region, 60126 Ancona-Torrette, Italy.
Marche Polytechnic University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDA) remains one of the most aggressive tumors with a low rate of survival. Surgery is the only curative treatment for PDA, although only 20% of patients are resectable at diagnosis. During the last decade there was an improvement in survival in patients affected by PDA, possibly explained by the advances in cancer therapy and by improve patient selection by pancreatic surgeons. It is necessary to select patients not only on the basis of surgical resectability, but also on the basis of the biological nature of the tumor. Specific preoperative criteria can be identified in order to select patients who will benefit from surgical resection. Duration of symptoms and level of carbohydrate antigen 19.9 in resectable disease should be considered to avoid R1 resection and early relapse. Radiological assessment can help surgeons to distinguish resectable disease from borderline resectable disease and locally advanced pancreatic cancer. Better patient selection can increase survival rate and neoadjuvant treatment can help surgeons select patients who will benefit from surgery.

Indexed as

PancreatectomyPatient SelectionAnimalsBiomarkersCA-19-9 AntigenCarcinoma, Pancreatic DuctalDecision Support TechniquesDiagnostic ImagingHumansNeoplasm Recurrence, LocalNeoplasm StagingPancreatic NeoplasmsPredictive Value of TestsRadiographyRisk AssessmentRisk FactorsBiomarkersCA-19-9 AntigenBorderline resectable pancreatic cancerPancreatic cancerPancreatic cancer stagingPancreatic ductal adenocarcinomaPancreatic surgery

Identifiers

PMID25170205
PMCPMC4145759
OpenAlexW2004416150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.